HEROHE Challenge: assessing HER2 status in breast cancer without immunohistochemistry or in situ hybridization
Authors:
Eduardo Conde-Sousa,
João Vale,
Ming Feng,
Kele Xu,
Yin Wang,
Vincenzo Della Mea,
David La Barbera,
Ehsan Montahaei,
Mahdieh Soleymani Baghshah,
Andreas Turzynski,
Jacob Gildenblat,
Eldad Klaiman,
Yiyu Hong,
Guilherme Aresta,
Teresa Araújo,
Paulo Aguiar,
Catarina Eloy,
António Polónia
Abstract:
Breast cancer is the most common malignancy in women, being responsible for more than half a million deaths every year. As such, early and accurate diagnosis is of paramount importance. Human expertise is required to diagnose and correctly classify breast cancer and define appropriate therapy, which depends on the evaluation of the expression of different biomarkers such as the transmembrane prote…
▽ More
Breast cancer is the most common malignancy in women, being responsible for more than half a million deaths every year. As such, early and accurate diagnosis is of paramount importance. Human expertise is required to diagnose and correctly classify breast cancer and define appropriate therapy, which depends on the evaluation of the expression of different biomarkers such as the transmembrane protein receptor HER2. This evaluation requires several steps, including special techniques such as immunohistochemistry or in situ hybridization to assess HER2 status. With the goal of reducing the number of steps and human bias in diagnosis, the HEROHE Challenge was organized, as a parallel event of the 16th European Congress on Digital Pathology, aiming to automate the assessment of the HER2 status based only on hematoxylin and eosin stained tissue sample of invasive breast cancer. Methods to assess HER2 status were presented by 21 teams worldwide and the results achieved by some of the proposed methods open potential perspectives to advance the state-of-the-art.
△ Less
Submitted 8 November, 2021;
originally announced November 2021.
Automated Scoring of Nuclear Pleomorphism Spectrum with Pathologist-level Performance in Breast Cancer
Authors:
Caner Mercan,
Maschenka Balkenhol,
Roberto Salgado,
Mark Sherman,
Philippe Vielh,
Willem Vreuls,
Antonio Polonia,
Hugo M. Horlings,
Wilko Weichert,
Jodi M. Carter,
Peter Bult,
Matthias Christgen,
Carsten Denkert,
Koen van de Vijver,
Jeroen van der Laak,
Francesco Ciompi
Abstract:
Nuclear pleomorphism, defined herein as the extent of abnormalities in the overall appearance of tumor nuclei, is one of the components of the three-tiered breast cancer grading. Given that nuclear pleomorphism reflects a continuous spectrum of variation, we trained a deep neural network on a large variety of tumor regions from the collective knowledge of several pathologists, without constraining…
▽ More
Nuclear pleomorphism, defined herein as the extent of abnormalities in the overall appearance of tumor nuclei, is one of the components of the three-tiered breast cancer grading. Given that nuclear pleomorphism reflects a continuous spectrum of variation, we trained a deep neural network on a large variety of tumor regions from the collective knowledge of several pathologists, without constraining the network to the traditional three-category classification. We also motivate an additional approach in which we discuss the additional benefit of normal epithelium as baseline, following the routine clinical practice where pathologists are trained to score nuclear pleomorphism in tumor, having the normal breast epithelium for comparison. In multiple experiments, our fully-automated approach could achieve top pathologist-level performance in select regions of interest as well as at whole slide images, compared to ten and four pathologists, respectively.
△ Less
Submitted 24 December, 2020; v1 submitted 9 December, 2020;
originally announced December 2020.
